NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free AMRN Stock Alerts $0.85 -0.03 (-3.40%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.85▼$0.9050-Day Range$0.82▼$1.0752-Week Range$0.65▼$1.49Volume1.28 million shsAverage Volume1.04 million shsMarket Capitalization$350.10 millionP/E RatioN/ADividend YieldN/APrice Target$1.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Amarin alerts: Email Address Amarin MarketRank™ Stock AnalysisAnalyst RatingReduce1.75 Rating ScoreUpside/Downside27.1% Upside$1.08 Price TargetShort InterestBearish3.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.16) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.74 out of 5 starsMedical Sector839th out of 921 stocksPharmaceutical Preparations Industry395th out of 428 stocks 2.9 Analyst's Opinion Consensus RatingAmarin has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.Amount of Analyst CoverageAmarin has received no research coverage in the past 90 days.Read more about Amarin's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted3.94% of the outstanding shares of Amarin have been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Amarin has recently increased by 2.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMRN. Previous Next 2.4 News and Social Media Coverage News SentimentAmarin has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amarin this week, compared to 2 articles on an average week.Search Interest14 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.16) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -7.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -7.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amarin's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Amarin Stock (NASDAQ:AMRN)Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Read More AMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMRN Stock News HeadlinesMay 6, 2024 | globenewswire.comAmarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 4, 2024 | americanbankingnews.comQ2 2025 EPS Estimates for Amarin Co. plc Lowered by Zacks Research (NASDAQ:AMRN)May 11, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.May 3, 2024 | finance.yahoo.comAmarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comAmarin First Quarter 2024 Earnings: EPS Beats ExpectationsMay 1, 2024 | markets.businessinsider.comAmarin’s Sell Rating Affirmed Amid US Market Challenges and Uncertain European GrowthMay 1, 2024 | finance.yahoo.comAmarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic FocusMay 1, 2024 | fool.comAmarin Plc (AMRN) Q1 2024 Earnings Call TranscriptMay 11, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.May 1, 2024 | investorplace.comAMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024May 1, 2024 | globenewswire.comAmarin Reports First Quarter 2024 Business Update and Financial ResultsApril 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from Amarin's earnings reportApril 30, 2024 | msn.comAmarin Q1 2024 Earnings PreviewApril 24, 2024 | finance.yahoo.comAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventApril 24, 2024 | globenewswire.comAmarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventApril 22, 2024 | globenewswire.comAmarin Announces Results of Annual General Meeting of ShareholdersApril 18, 2024 | seekingalpha.comAmarin Corporation: Small Signs Of Recovery May Not Be EnoughApril 15, 2024 | globenewswire.comAmarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024April 8, 2024 | finanznachrichten.deAmarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsApril 8, 2024 | globenewswire.comAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24April 6, 2024 | globenewswire.comNew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsApril 3, 2024 | fool.comWhy Amarin Stock Was Rocketing Higher on WednesdayApril 3, 2024 | markets.businessinsider.comAmarin: IP Protection For VAZKEPA In Europe Now Extended Into 2039 - Quick FactsApril 3, 2024 | globenewswire.comAmarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in EuropeMarch 25, 2024 | finance.yahoo.comResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & ExpoMarch 25, 2024 | globenewswire.comResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoMarch 16, 2024 | finance.yahoo.comAMRN Apr 2024 3.000 callSee More Headlines Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/11/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMRN CUSIPN/A CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees275Year Founded1991Price Target and Rating Average Stock Price Target$1.08 High Stock Price Target$1.25 Low Stock Price Target$1.00 Potential Upside/Downside+27.1%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,110,000.00 Net Margins-18.96% Pretax Margin-17.24% Return on Equity-9.48% Return on Assets-6.34% Debt Debt-to-Equity RatioN/A Current Ratio3.07 Quick Ratio1.93 Sales & Book Value Annual Sales$306.91 million Price / Sales1.14 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book0.64Miscellaneous Outstanding Shares410,670,000Free Float402,623,000Market Cap$350.10 million OptionableOptionable Beta1.96 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Patrick J. Holt (Age 51)President, CEO & Director Comp: $678.88kMr. Thomas Charles Reilly (Age 51)Executive VP, CFO & Global Head of HR Comp: $1.01MDr. Steven B. Ketchum Ph.D. (Age 59)Executive VP, President of Research & Development and Chief Scientific Officer Comp: $1.16MMr. Jonathan N. Provoost (Age 54)Executive VP, Chief Legal & Compliance Officer and Secretary Comp: $160.08kMr. Aaron D. Berg (Age 61)Executive VP & President of U.S. Comp: $1.26MMr. Jordan Zwick (Age 37)Senior VP of Corporate Business Development & Investor Relations Mr. Laurent AbuafPresident of Europe & Senior VPDr. Nabil AbadirChief Medical Officer of Global Medical AffairsDr. David Keenan Ph.D.Executive VP of Technical Operations & President of EuropeMore ExecutivesKey CompetitorsADC TherapeuticsNYSE:ADCTAlto NeuroscienceNYSE:ANROHarrowNASDAQ:HROWCorbus PharmaceuticalsNASDAQ:CRBPErascaNASDAQ:ERASView All CompetitorsInsiders & InstitutionsLongitude Cayman Ltd.Sold 895,000 shares on 5/10/2024Ownership: 0.573%Significant Wealth Partners LLCBought 19,461 shares on 5/7/2024Ownership: 0.008%LCM Capital Management IncBought 68,000 shares on 5/6/2024Ownership: 0.197%GSA Capital Partners LLPBought 632,497 shares on 5/3/2024Ownership: 0.361%Mirae Asset Global Investments Co. Ltd.Sold 57,817 shares on 5/1/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions AMRN Stock Analysis - Frequently Asked Questions Should I buy or sell Amarin stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" AMRN shares. View AMRN analyst ratings or view top-rated stocks. What is Amarin's stock price target for 2024? 4 Wall Street research analysts have issued 1 year price targets for Amarin's shares. Their AMRN share price targets range from $1.00 to $1.25. On average, they expect the company's stock price to reach $1.08 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price. View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts. How have AMRN shares performed in 2024? Amarin's stock was trading at $0.87 at the beginning of 2024. Since then, AMRN shares have decreased by 2.0% and is now trading at $0.8525. View the best growth stocks for 2024 here. When is Amarin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our AMRN earnings forecast. How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company had revenue of $56.52 million for the quarter, compared to the consensus estimate of $51.34 million. Amarin had a negative net margin of 18.96% and a negative trailing twelve-month return on equity of 9.48%. During the same quarter last year, the firm earned ($0.04) EPS. What is John Thero's approval rating as Amarin's CEO? 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX). Who are Amarin's major shareholders? Amarin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Longitude Cayman Ltd. (0.57%), GSA Capital Partners LLP (0.36%), BNP Paribas Financial Markets (0.23%), LCM Capital Management Inc (0.20%), Simplicity Wealth LLC (0.11%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include David M Stack, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Amarin have any subsidiaries? The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.Read More This page (NASDAQ:AMRN) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
